Raphael Pharmaceutical (RAPH) Short term Debt (2020 - 2025)

Raphael Pharmaceutical has disclosed Short term Debt across 5 years of filings, most recently posting $34000.0 for Q4 2025.

• Short term Debt for Q4 2025 came in at $34000.0, down 17.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $34000.0 (down 17.07% YoY), and the FY2025 annual result was $34000.0, down 17.07% from the prior year.
• Short term Debt came in at $34000.0 for Q4 2025 at Raphael Pharmaceutical, down from $41000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $41000.0 in Q4 2024 to a low of $1000.0 in Q1 2022.
• The 4-year median for Short term Debt is $34000.0 (2025), against an average of $26444.4.
• Across the five-year window, Short term Debt soared 144.44% in 2021 and tumbled 86.36% in 2022, its largest moves.
• Raphael Pharmaceutical's Short term Debt stood at $22000.0 in 2021, then sank by 86.36% to $3000.0 in 2022, then surged by 1266.67% to $41000.0 in 2024, then retreated by 17.07% to $34000.0 in 2025.
• The last three Short term Debt figures came in at $34000.0 (Q4 2025), $41000.0 (Q3 2025), and $41000.0 (Q2 2025), per Business Quant data.